-
公开(公告)号：WO2009042962A3
公开(公告)日：2009-06-04
申请号：PCT/US2008078014
申请日：2008-09-26
Applicant: PORTOLA PHARM INC , LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
Inventor： LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
CPC classification number: A61K38/4846 , A61K38/00 , A61K38/4826 , A61K38/4833 , A61K38/4853 , A61K39/00 , A61K47/60 , C07K14/435 , C12N9/6432 , C12Y304/21006
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract translation: 本发明涉及解毒剂靶向因子Xa的抗凝血剂。 解毒剂是因子Xa蛋白衍生物，其与因子Xa抑制剂结合，从而基本上中和它们但不组装成凝血酶原酶复合物。 本文描述的衍生物缺乏或降低了内在凝固剂活性。 本文公开了停止或预防正在用Xa因子抑制剂进行抗凝血剂治疗的患者出血的方法。
-
公开(公告)号：WO2010117729A1
公开(公告)日：2010-10-14
申请号：PCT/US2010/029064
申请日：2010-03-29
Applicant: PORTOLA PHARMACEUTICALS, INC. , SINHA, Uma , LU, Genmin , CONLEY, Pamela B.
Inventor： SINHA, Uma , LU, Genmin , CONLEY, Pamela B.
CPC classification number: C12N9/6432 , A61K38/482 , A61K38/4826 , A61K38/4833 , A61K38/4846 , A61K38/4853 , A61K39/00 , A61K47/60 , C12Y304/21006
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor X and factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of reversing anticoagulation, stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract translation: 本发明涉及靶向因子Xa的抗凝剂的解毒剂。 解毒剂是与因子Xa抑制剂结合的因子X和因子Xa蛋白衍生物，从而基本上中和它们，但不组装到凝血酶原酶复合物中。 本文所述的衍生物缺乏或具有降低的内在凝结剂活性。 本文公开的是使用因子Xa抑制剂正在进行抗凝治疗的患者中的抗凝，停止或预防出血的方法。
-
Patent Agency Ranking3.发明申请ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS 审中-公开因子XA抑制剂的抗体及其与血液凝血剂联合使用的方法
公开(公告)号：WO2010056765A2
公开(公告)日：2010-05-20
申请号：PCT/US2009/064060
申请日：2009-11-11
Applicant: PORTOLA PHARMACEUTICALS, INC. , LU, Genmin , SINHA, Uma
Inventor： LU, Genmin , SINHA, Uma
CPC classification number: A61K38/36 , A61K35/16 , A61K38/16 , A61K38/37 , A61K38/482 , A61K38/4826 , A61K38/4833 , A61K38/4846 , A61K38/4853 , A61K45/06 , A61K2300/00
Abstract: The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract translation: 本发明涉及抗凝剂靶向因子Xa的解毒剂，该解毒剂与凝血剂或其他肝素解毒剂组合使用以预防或减少受试者的出血。 本文所述的解毒剂具有降低或没有固有的凝结剂活性。 本文公开的是在患者中停止或预防出血的方法，该患者将使用因子Xa抑制剂进行或将要进行抗凝治疗。
-
4.发明申请ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME IN COMBINATION WITH BLOOD COAGULATING AGENTS 审中-公开用于因子XA抑制剂的抗体及其与血液凝结剂组合使用的方法
公开(公告)号：WO2010056765A3
公开(公告)日：2010-08-05
申请号：PCT/US2009064060
申请日：2009-11-11
Applicant: PORTOLA PHARM INC , LU GENMIN , SINHA UMA
CPC classification number: A61K38/36 , A61K35/16 , A61K38/16 , A61K38/37 , A61K38/482 , A61K38/4826 , A61K38/4833 , A61K38/4846 , A61K38/4853 , A61K45/06 , A61K2300/00
Abstract: The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract translation: 本发明涉及靶向凝血因子Xa的抗凝剂的解毒剂，其中解毒剂与凝血剂或其他肝素解毒剂组合使用以预防或减少受试者的出血。 本文所述的解毒剂具有降低的或不具有内在凝固剂活性。 本文公开了停止或预防正在或将要用Xa因子抑制剂进行抗凝血剂治疗的患者出血的方法。
-
公开(公告)号：WO2009042962A9
公开(公告)日：2009-04-02
申请号：PCT/US2008/078014
申请日：2008-09-26
Applicant: PORTOLA PHARMACEUTICALS, INC. , LU, Genmin , PHILLIPS, David R. , ANDRE, Patrick , SINHA, Uma
Inventor： LU, Genmin , PHILLIPS, David R. , ANDRE, Patrick , SINHA, Uma
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
-
6.发明申请UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME 审中-公开单元剂量制剂对于XA抑制因子的抗体及其使用方法
公开(公告)号：WO2011008885A1
公开(公告)日：2011-01-20
申请号：PCT/US2010/042015
申请日：2010-07-14
Applicant: PORTOLA PHARMACEUTICALS, INC. , SINHA, Uma , LU, Genmin , HUTCHALEELAHA, Athiwat , HOLLENBACH, Stanley J.
Inventor： SINHA, Uma , LU, Genmin , HUTCHALEELAHA, Athiwat , HOLLENBACH, Stanley J.
CPC classification number: A61K38/4846 , A61K9/0019 , C12N9/6432 , C12Y304/21006
Abstract: The present invention relates unit dose formulations of antidotes to anticoagulants targeting factor Xa. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract translation: 本发明涉及解毒剂的单位剂量制剂与靶向因子Xa的抗凝剂。 本文公开了在目前正在进行使用因子Xa抑制剂进行抗凝治疗的患者中停止或预防出血的方法。
-
公开(公告)号：WO2009042962A2
公开(公告)日：2009-04-02
申请号：PCT/US2008078014
申请日：2008-09-26
Applicant: PORTOLA PHARM INC , LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
Inventor： LU GENMIN , PHILLIPS DAVID R , ANDRE PATRICK , SINHA UMA
IPC: A61P7/02 , A61K31/4545 , A61K31/5377 , A61K31/715 , A61K31/727 , A61K38/36 , A61K38/48 , A61K39/395 , A61K47/48 , A61P7/04 , C07H21/00 , C07K14/00 , C07K16/00 , C12N5/10 , C12P21/00
CPC classification number: A61K38/4846 , A61K38/00 , A61K38/4826 , A61K38/4833 , A61K38/4853 , A61K39/00 , A61K47/60 , C07K14/435 , C12N9/6432 , C12Y304/21006
Abstract: The present invention relates antidotes to anticoagulants targeting factor Xa. The antidotes are factor Xa protein derivatives that bind to the factor Xa inhibitors thereby substantially neutralizing them but do not assemble into the prothrombinase complex. The derivatives describe herein lack or have reduced intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is currently undergoing anticoagulant therapy with a factor Xa inhibitor.
Abstract translation: 本发明涉及靶向因子Xa的抗凝剂的解毒剂。 解毒剂是与因子Xa抑制剂结合的因子Xa蛋白衍生物，从而基本上中和它们，但不组装到凝血酶原酶复合物中。 本文所述的衍生物缺乏或具有降低的内在凝结剂活性。 本文公开了在目前正在进行使用因子Xa抑制剂进行抗凝治疗的患者中停止或预防出血的方法。
-
-
-
-
-
-
Search Results
7
records
(took 0.016 seconds)
